Continued Administration of G-202 for One Patient With Advanced Hepatocellular Carcinoma
- Conditions
- Hepatocellular Carcinoma
- Registration Number
- NCT02082691
- Lead Sponsor
- Devalingam Mahalingam
- Brief Summary
Patient with advanced liver cancer (cancer that has spread to other parts of the body) continues to receive the study drug (G-202) even though patient no longer meets the criteria to be a part of the main treatment study. Patient's cancer responded well to receiving G-202 in the main study and will receive G-202 at the same dose given in the main study.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NO_LONGER_AVAILABLE
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- History of hepatocellular carcinoma
- Participation in prior research study where G-202 was administered
- Tolerance of G-202 treatment
- Demonstration of stable disease
Exclusion Criteria
- Disease progression
- Occurrence of unacceptable toxicity
Study & Design
- Study Type
- EXPANDED_ACCESS
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method